louisbrulenaudet/clinical-trials huggingface dataset:
Clinical trial NCT00887900: Deep Anterior Lamellar Keratoplasty (DALK)
Official title: Deep Anterior Lamellar Keratoplasty by Big-Bubble Technique: Results and Complications
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: PHASE3
Conditions: Keratoconus
Keywords: lamellar keratoplasty
keratoconus
penetrated keratoplasty
Visual acuity
Lead sponsor: Hospital Oftalmologico de Brasilia
Sponsor class: OTHER
First posted: 2009-04-24
Enrollment: 40
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: NON_RANDOMIZED
Intervention model: SINGLE_GROUP
Primary purpose: TREATMENT

Brief summary: The purpose of this study is to report outcomes of deep anterior lamellar keratoplasty (DALK) using the big-bubble technique.

Detailed description: Purpose: To report outcomes of deep anterior lamellar keratoplasty (DALK) using the big-bubble technique.

Methods: Thirty four unselected consecutive patients were submitted to DALK big-bubble technique. Intraoperative and postoperative complications, postoperative uncorrected visual acuity (UCVA), best spectacle-corrected visual acuity (BSCVA), spherical equivalent (SE), corneal topography, and endothelial cell density were evaluated. All patients were followed for at least 6 months.

Eligibility criteria: Inclusion Criteria:

* keratoconus

Exclusion Criteria:

* central endothelial cell count less than 2000 cells/mm2
* glaucoma or intraocular pressure greater than 21 mmHg
* amblyopia
* retinal abnormalities
* diabetes mellitus
* steroid or immunosuppressive treatment
* connective tissue diseases

Primary outcomes:
measure: To report outcomes of deep anterior lamellar keratoplasty (DALK) using the big-bubble technique.
timeFrame: 12 months
Secondary outcomes:
Other outcomes:
Locations:
city: Brasília
country: Brazil
facility: Hospital Oftalmologico de Brasília
state: DF
Study officials:
affiliation: Federal University of Minas Gerais
name: PATRICK F TZELIKIS, PhD, MD
role: PRINCIPAL_INVESTIGATOR
References:
citation: Tan DT, Parthasarathy A. Deep anterior lamellar keratoplasty for keratoconus. Cornea. 2007 Sep;26(8):1025; author reply 1025-6. doi: 10.1097/ICO.0b013e31805771e3. No abstract available.
citation: Vajpayee RB, Tyagi J, Sharma N, Kumar N, Jhanji V, Titiyal JS. Deep anterior lamellar keratoplasty by big-bubble technique for treatment corneal stromal opacities. Am J Ophthalmol. 2007 Jun;143(6):954-957. doi: 10.1016/j.ajo.2007.02.036. Epub 2007 Apr 16.
citation: Ardjomand N, Hau S, McAlister JC, Bunce C, Galaretta D, Tuft SJ, Larkin DF. Quality of vision and graft thickness in deep anterior lamellar and penetrating corneal allografts. Am J Ophthalmol. 2007 Feb;143(2):228-235. doi: 10.1016/j.ajo.2006.10.043. Epub 2006 Nov 30.
citation: Tzelikis PF, Santos JD, Garcez RC, Akaishi L. [Deep anterior lamellar keratoplasty by big-bubble technique]. Arq Bras Oftalmol. 2011 Nov-Dec;74(6):435-40. doi: 10.1590/s0004-27492011000600011. Portuguese.
Clinical trial NCT06091800: Interleukin 20 and Periodontal Tisuue Destruction
Official title: Determination of Levels of IL-20, TNF-α, IL1β/IL-10, RANKL/OPG and MMP8 in Serum and Gingival Crevicular Fluid (GCF) in Peridontally Healthy and Periodontitis Individuals
Study type: OBSERVATIONAL
Overall status: COMPLETED
Conditions: Periodontitis
Lead sponsor: Recep Tayyip Erdogan University
Sponsor class: OTHER
First posted: 2023-10-19
Enrollment: 60
Sex: ALL
Minimum age (years): 20
Maximum age (years): 65
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: yes
Observational model: CASE_CONTROL
Time perspective: CROSS_SECTIONAL
Sampling method: PROBABILITY_SAMPLE
Study population: This study included individuals who applied to Recep Tayyip Erdogan University, Faculty of Dentistry, Department of Periodontology for treatment

Brief summary: Periodontitis is an inflammatory disease that causes destruction of periodontal tissues. IL-20, on the other hand, is known as a potent angiogenic, chemotactic, and pro-inflammatory cytokine associated with various chronic inflammatory disorders. IL-20 has a significant role in the regulation of osteoclastogenesis and osteoblastogenesis. The aim of this study was to evaluate the effect of IL-20 on periodontal destruction.

In the study, a total of 60 participants were included, 30 of whom were systemically and periodontally healthy (control group) and 30 of whom were systemically healthy and had periodontitis (periodontitis group). GCF and serum samples were collected from the participants for biochemical analysis. ELISA method was used to determine IL-20, TNF-α, IL1β/IL-10, RANKL/OPG and MMP8 levels


Eligibility criteria: Inclusion Criteria:

* The following criteria were required for inclusion: being systemically healthy, not smoking, not using antibiotics or systemic corticosteroids within the previous three months, not being pregnant or nursing, not having a chronic inflammatory disease, not receiving periodontal therapy within the previous six months, and possessing at least 20 teeth

Exclusion Criteria:

* smoking, using antibiotics or systemic corticosteroids within the previous three months, pregnant, receiving periodontal therapy within the previous six months

Primary outcomes:
measure: concentration of biochemical findings in gingival crevicular fluid (GCF)
timeFrame: june 2022-june 2023
measure: concentration of biochemical findings in serum
timeFrame: 1 year
Secondary outcomes:
measure: value of periodontal clinical parameters
timeFrame: 1 year
measure: value of periodontal clinical parameters were measured in mm
timeFrame: 1 year
Other outcomes:
Locations:
city: Rize
country: Turkey
facility: Recep Tayyip Erdogan University
Study officials:
affiliation: Recep Tayyip Erdogan University
name: Yemenoglu
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT00293800: A Study of Glaucoma Therapy to Treat Open-Angle Glaucoma or Ocular Hypertension
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: PHASE3
Conditions: Open-Angle Glaucoma
Ocular Hypertension
Keywords: Open-angle
glaucoma
ocular
hypertension
Lead sponsor: Alcon Research
Sponsor class: INDUSTRY
First posted: 2006-02-20
Enrollment: 173
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: TREATMENT

Brief summary: The purpose of the study is to evaluate the safety and effectiveness of an investigational glaucoma therapy in patients with open-angle glaucoma or ocular hypertension.


Eligibility criteria: Inclusion Criteria:

* 18 years or older.
* Diagnosis of open-angle glaucoma (with or without pseudoexfoliation or pigment dispersion component) or ocular hypertension.
* Mean intraocular pressure (IOP) in at least one eye greater than 21 mmHg and less than or equal to 36 mmHg at screening visit.
* Other protocol-defined inclusion criteria may apply.

Exclusion Criteria:

* Pregnant
* History of chronic or recurrent severe inflammatory eye disease.
* History of ocular infection or ocular inflammation within the past three months in either eye.
* Other protocol-defined exclusion criteria may apply.

Primary outcomes:
measure: Mean Intraocular Pressure (IOP) Change at 3 Months from Baseline
timeFrame: 3 months
Secondary outcomes:
Other outcomes:
Locations:
Study officials:
References:
Clinical trial NCT04149600: Identification of Genetic Causes of Calcific Aortic Valve Disease
Official title: Identification of Genetic Causes of Calcific Aortic Valve Disease
Study type: OBSERVATIONAL
Overall status: ACTIVE_NOT_RECRUITING
Conditions: Calcific Aortic Stenosis
Calcific Aortic Stenosis - Bicuspid Valve
Aortic Valve Disease
Aortic Valve Calcification
Aortic Diseases
Aortic Aneurysm
Aortic Valve Cusp Abnormality
Aortic Valve Disease Mixed
Aortic Valve Insufficiency
Lead sponsor: Beth Israel Deaconess Medical Center
Sponsor class: OTHER
Collaborators: name: Brigham and Women's Hospital
First posted: 2019-11-04
Enrollment: 1000
Sex: ALL
Minimum age (years): 20
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: yes
Observational model: COHORT
Time perspective: PROSPECTIVE
Sampling method: NON_PROBABILITY_SAMPLE
Study population: The investigators wish to identify the molecular genetic causes of the variability in development of calcific aortic valve disease and aortic dilation in patients with a plan to undergo elective aortic valve replacement and/or ascending aortic surgery at BIDMC.

Brief summary: This study aims to identify the molecular genetic causes of the variability in development of calcific aortic valve disease in bicuspid and tricuspid aortic valves and their associated aortic dilation.


Eligibility criteria: Inclusion Criteria:

* Patients with a plan to undergo elective aortic valve replacement and/or ascending aortic surgery

Exclusion Criteria:

* Age \< 20 years
* Unable/unwilling to consent
* History of aortic valve replacement or transcatheter aortic valve replacement (TAVR)
* History of endocarditis
* History of rheumatic fever
* History of chest radiotherapy
* History of organ transplant

Primary outcomes:
measure: Identification of expression signatures of aortic valve development and calcification in the macroscopically normal and abnormal portions of aortic valves excised during aortic valve replacement.
timeFrame: 8 years
Secondary outcomes:
Other outcomes:
Locations:
city: Boston
country: United States
facility: Beth Israel Deaconess Medical Center
state: Massachusetts
Study officials:
References:
Clinical trial NCT01791400: Effect of Metoclopramide Versus Sumatriptan for Emergency Department Treatment of Migraine Headache
Official title: Study of Effects of Metoclopramide Versus Sumatriptan on Migraine Headache
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: PHASE2
Conditions: Migraine Disorders
Keywords: Metoclopramide
Sumatriptan
migraine
headache
Lead sponsor: Isfahan University of Medical Sciences
Sponsor class: OTHER
First posted: 2013-02-15
Enrollment: 124
Sex: ALL
Minimum age (years): 20
Maximum age (years): 60
Standard ages: ADULT
Accepts healthy volunteers: yes
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: TREATMENT

Brief summary: The purpose of this study is to determine which drug makes lower migraine headache

Detailed description: There are different options to manage benign headache in emergency department.The investigators compared Intravenous metoclopramide with Subcutaneous sumatriptan to relieve pain in emergency department.

Eligibility criteria: Inclusion Criteria:

* 20-60 years old and presented with acute headache similar to previous episodes,
* with or without phonophobia,
* photophobia,
* vomiting or nausea.

Exclusion Criteria:

* fever or neck stiffness,
* altered mental state,
* pregnancy,
* recent trauma or seizure (within 24 hours),
* focal neurological abnormality on physical examination,
* allergy to metoclopramide,
* hypertension,
* cardiovascular diseases.

Also if the patients had taken a triptan or ergot during the last 24 hours were excluded from the study.

Primary outcomes:
measure: pain
timeFrame: at one hour after prescription
Secondary outcomes:
Other outcomes:
Locations:
city: Isfahan
country: Iran, Islamic Republic of
facility: Al-zahra university hospital
Study officials:
affiliation: Isfahan, Isfahan, Iran, Islamic Republic of
name: babak masoumi, A.Professor
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT01926600: Sublingual Administration of PPI
Official title: Sublingual Administration is More Fast Than Oral or IV Administration in PPI Dosing With Respect to Intragastric pH and Therapeutic Effectiveness: a Prospective, Randomized, Controlled Trial
Study type: OBSERVATIONAL
Overall status: UNKNOWN
Conditions: Gastric or Duodenal Ulcer
Keywords: gastric ulcer
duodenal ulcer
re-bleeding rate
intragastric pH
proton pump inhibitor
Lead sponsor: The Catholic University of Korea
Sponsor class: OTHER
First posted: 2013-08-21
Enrollment: 60
Sex: ALL
Minimum age (years): 20
Maximum age (years): 75
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Observational model: CASE_CONTROL
Time perspective: PROSPECTIVE
Sampling method: PROBABILITY_SAMPLE
Study population: 3 groups, each group with 20 subject with peptic ulcer ages between 20 to 75

Brief summary: Compare 24-hour intragastric pH and therapeutic effectiveness of proton pump inhibitor (PPI) among different administration methods: per oral (PO), intravenous (IV), and sublingual (SL).

Detailed description: Intragastric pH and therapeutic effectiveness of PPI was compared among patients given PPI with different administration methods. 24 hour intragastric pH catheter was inserted in stomach of patients with peptic ulcer an hour prior to PPI administration in order to observe the initial change in pH. Three groups of patients were given PPI through per oral, intravenous, and sublingual administration methods. The hypothesis of this study is that sublingual administration will be faster than oral or IV administration in PPI dosing with respect to intragastric pH change and re-bleeding rate.

Eligibility criteria: Inclusion Criteria:

* Patients with peptic ulcer disease
* Age: 20-75 years old
* Patients who submitted informed consent

Exclusion Criteria:

* Peptic ulcer disease with spurting and oozing
* Shock, hypotension, pregnancy
* Gastrointestinal malignancy

Primary outcomes:
measure: Measure 24-hour intragastric pH
timeFrame: 24 hours
Secondary outcomes:
Other outcomes:
Locations:
city: Seoul
country: Korea, Republic of
facility: St.Mary's Hopspital of the Catholic University
Study officials:
References:
Clinical trial NCT01929200: Icotinib as Adjuvant Therapy in Treating Non-small-cell Lung Cancer Patients With Positive EGFR Mutation
Official title: Randomized, Open-label, Multicenter Study of Icotinib as Adjuvant Therapy in Treating Stage II-IIIA Non-small-cell Lung Cancer Patients With Positive EGFR Mutation
Study type: INTERVENTIONAL
Overall status: UNKNOWN
Phase: PHASE2
Conditions: Non-small-cell Lung Cancer
Lead sponsor: Betta Pharmaceuticals Co., Ltd.
Sponsor class: INDUSTRY
First posted: 2013-08-27
Enrollment: 120
Sex: ALL
Minimum age (years): 18
Maximum age (years): 75
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: TREATMENT

Brief summary: This study is designed to evaluate the efficacy of icotinib as adjuvant therapy in treating such patients. The primary endpoint is to compare the recurrence-free survival after 1-year or 2-year treatment with icotinib.

Detailed description: Adjuvant therapy has been proved effective in treating stage II-IIIA non-small-cell lung cancer. However, few data on the treating time of adjuvant therapy is available. Here we conduct a randomized, prospective study to compare the recurrence-free survival after 1-year or 2-year treatment with icotinib in EGFR-mutated non-small cell lung cancer patients.

Eligibility criteria: Inclusion Criteria:

* The patients signed the written informed consent
* The patients present with operable stage II-IIIA non-small-cell lung cancers with 19 or 21 exon mutation
* The patients have no history of anti-cancer therapies including chemotherapy, radiation therapy
* The patients' Eastern Cooperative Oncology Group scores are ≤ 0-2

Exclusion Criteria:

* Patients with unresected tumor
* Wild EGFR type
* Allergic to the study drug
* Patients have severe non-cancerous diseases
* Patients are undergoing current administration of anti-cancer therapies, or are attending some other clinical trials

Primary outcomes:
measure: Recurrence-free Survival
timeFrame: 6 months
Secondary outcomes:
measure: Overall survival
timeFrame: 6 months
Other outcomes:
Locations:
city: Beijing
country: China
facility: Beijing Cancer hospital
Study officials:
affiliation: Peking University Cancer Hospital & Institute
name: Yue Yang, MD
role: PRINCIPAL_INVESTIGATOR
References:
citation: Lv C, Ma Y, Feng Q, Fang F, Bai H, Zhao B, Yan S, Wu N, Zheng Q, Li S, Chen J, Wang J, Feng Y, Wang Y, Pei Y, Fang J, Yang Y. A pilot study: sequential gemcitabine/cisplatin and icotinib as induction therapy for stage IIB to IIIA non-small-cell lung adenocarcinoma. World J Surg Oncol. 2013 Apr 26;11:96. doi: 10.1186/1477-7819-11-96.
Clinical trial NCT04534400: Automated Quantification of Radiologic Pulmonary Alteration During Acute Respiratory Failure
Official title: Automated Quantification of Radiologic Pulmonary Alteration During Acute Respiratory Failure: Application to the COVID-19 Pandemic
Study type: OBSERVATIONAL
Overall status: UNKNOWN
Conditions: SARS-CoV-2 Infection
Respiratory Failure With Hypoxia
Lead sponsor: University Hospital, Strasbourg, France
Sponsor class: OTHER
Collaborators: name: VISIBLE PATIENT, E-MEDIA
First posted: 2020-09-01
Enrollment: 1000
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Observational model: COHORT
Time perspective: RETROSPECTIVE
Sampling method: NON_PROBABILITY_SAMPLE
Study population: Hospitalized patients that underwent a thoracic CT-scan

Brief summary: Automated quantification of the pulmonary volume impaired during acute respiratory failure could be helpful to assess patient severity during COVID-19 infection or perioperative medicine, for example.

This study aim at assessing the correlation between the amount of radiologic pulmonary alteration and the clinical severity in two clinical situation :

1. SARS-CoV-2 infections
2. Postoperative hypoxemic acute respiratory failure


Eligibility criteria: Inclusion Criteria:

* patient with insurance covering
* patient admitted to the participating hospitals for SARS-CoV-2 infection or postoperative acute hypoxemic respiratory failure between 01/01/2019 and 05/11/2020

Exclusion Criteria:

- patient transferred to another hospital than the participating center during the 7 days following the CT scan

Primary outcomes:
measure: Correlation between altered pulmonary volume and ordinal severity scale
timeFrame: 2 days after CT scan
Secondary outcomes:
measure: Correlation between altered pulmonary volume and ordinal severity scale
timeFrame: 7 days after CT scan
Other outcomes:
Locations:
city: Strasbourg
country: France
facility: HÔPITAUX UNIVERSITAIRES DE STRASBOURG, Hôpital de Hautepierre, Service de Réanimation Médicale
city: Vandœuvre-lès-Nancy
country: France
facility: Hôpitaux Universitaires de Nancy Service d'anesthésie réanimation Hôpital de Brabois
Study officials:
References:
Clinical trial NCT00010400: Pilot Study of Cyclophosphamide in Patients With Life-Threatening Systemic Lupus Erythematosus or Antiphospholipid Antibody Syndrome
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: NA
Conditions: Systemic Lupus Erythematosus
Antiphospholipid Antibody Syndrome
Keywords: antiphospholipid antibody syndrome
arthritis & connective tissue diseases
immunologic disorders and infectious disorders
rare disease
systemic lupus erythematosus
Lead sponsor: Office of Rare Diseases (ORD)
Sponsor class: NIH
First posted: 2001-02-02
Enrollment: 35
Sex: ALL
Minimum age (years): 18
Maximum age (years): 70
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: NON_RANDOMIZED
Primary purpose: TREATMENT

Brief summary: OBJECTIVES:

I. Determine the induction of durable remission in patients with life-threatening systemic lupus erythematosus or antiphospholipid antibody syndrome treated with cyclophosphamide.

II. Determine the toxicity of this drug in these patients.

Detailed description: PROTOCOL OUTLINE:

Patients receive cyclophosphamide IV on days 1-4 and filgrastim (G-CSF) beginning on day 10 and continuing until blood counts recover.

Patients are followed monthly for 6 months, and then every 3 months thereafter.

Eligibility criteria: PROTOCOL ENTRY CRITERIA:

--Disease Characteristics--

Diagnosis of life-threatening systemic lupus erythematosus (SLE); must show at least 4 American College of Rheumatology criteria for SLE; must have severe organ damage in 1 or more organs; must have 1 or more of the following indications of ongoing disease activity: disease activity score (SLEDAI) at least 4, hospitalization for disease activity within 12 months, life-threatening disease not captured on SLEDAI

OR

Diagnosis of antiphospholipid antibody syndrome by the Hughes criteria; must show severity by ongoing symptoms or signs of hypercoagulability in spite of warfarin therapy

--Patient Characteristics--

Hepatic: Bilirubin no greater than 2.0 mg/dL; transaminases no greater than 2.0 times normal

Renal: Creatinine no greater than 3.0 mg/dL

Cardiovascular: Ejection fraction at least 45%

Pulmonary: FVC, FEV1, or DLCO at least 50% predicted

Other: Not preterminal or moribund; not pregnant or nursing; fertile patients must use effective contraception

Primary outcomes:
Secondary outcomes:
Other outcomes:
Locations:
city: Baltimore
country: United States
facility: Johns Hopkins University School of Medicine
state: Maryland
city: Baltimore
country: United States
facility: Johns Hopkins Oncology Center
state: Maryland
Study officials:
affiliation: Johns Hopkins University
name: Robert A. Brodsky
role: STUDY_CHAIR
References:
citation: Petri M, Brodsky RA, Jones RJ, Gladstone D, Fillius M, Magder LS. High-dose cyclophosphamide versus monthly intravenous cyclophosphamide for systemic lupus erythematosus: a prospective randomized trial. Arthritis Rheum. 2010 May;62(5):1487-93. doi: 10.1002/art.27371.
Clinical trial NCT00794300: Reproducibility of Magnetic Resonance Myocardial Salvage Index
Official title: Reproducibility of Myocardial Salvage Index in Acute Myocardial Infarction by Cardiac Magnetic Resonance Imaging
Study type: OBSERVATIONAL
Overall status: COMPLETED
Conditions: Myocardial Infarction
Keywords: reproducibility
contrast agent
magnetic resonance imaging
infarct size
myocardial salvage index
myocardial salvage assessment
Lead sponsor: University of Leipzig
Sponsor class: OTHER
First posted: 2008-11-20
Enrollment: 250
Sex: ALL
Minimum age (years): 18
Maximum age (years): 99
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Observational model: COHORT
Time perspective: PROSPECTIVE
Sampling method: NON_PROBABILITY_SAMPLE
Study population: ST-elevation myocardial infarction

Brief summary: The myocardial salvage assessed by using multimodal cardiac magnetic resonance imaging is a rather new technique which can be used as a surrogate endpoint to reduce the sample size in studies comparing different reperfusion strategies in myocardial infarction. As reproducibility of myocardial salvage has not been evaluated appropriately, we aim to scan 20 patients on 2 subsequent days to evaluate reproducibility of myocardial salvage index.


Eligibility criteria: Inclusion Criteria:

* ST-elevation myocardial infarction
* Primary percutaneous coronary intervention

Exclusion Criteria:

* Contraindications for magnetic resonance imaging

Primary outcomes:
measure: Myocardial salvage index reproducibility
timeFrame: 2 days
Secondary outcomes:
measure: infarct size reproducibility
timeFrame: 2 days
measure: area at risk reproducibility
timeFrame: 2 days
measure: microvascular obstruction reproducibility
timeFrame: 2 days
Other outcomes:
Locations:
city: Leipzig
country: Germany
facility: University of Leipzig - Heart Center
Study officials:
affiliation: Heart Center Leipzig - University Hospital
name: Holger Thiele, MD
role: PRINCIPAL_INVESTIGATOR
References:
citation: Desch S, Engelhardt H, Meissner J, Eitel I, Sareban M, Fuernau G, de Waha S, Grothoff M, Gutberlet M, Schuler G, Thiele H. Reliability of myocardial salvage assessment by cardiac magnetic resonance imaging in acute reperfused myocardial infarction. Int J Cardiovasc Imaging. 2012 Feb;28(2):263-72. doi: 10.1007/s10554-011-9802-9. Epub 2011 Jan 30.